We are a clinician-led organisation where patient education and support services are initiated by the very people who treat breast cancer patients every day.
Your donation will help us enhance breast cancer treatment and care, and increase survival rates.
We began in 2009 with a vision to provide high quality care while conducting research that would deliver the most advanced treatments and save lives.
BCRC-WA conducts research into breast cancer treatment and care that underpins the treatment we provide to our patients.
BCRC-WA welcomes the news that Palbociclib (Ibrance) will be added to PBS for Australians with metastatic breast cancer from 1 May 2019.
Palbociclib (Ibrance) will only be available on the PBS as first line treatment for people newly diagnosed with metastatic hormone receptor positive, HER2-negative breast cancer from 1 May this year. To read more about this and how drugs are listed on the PBS visit the BCNA website.